2019
Design and analysis of longitudinal trials of antimicrobial use at the end of life: to give or not to give?
Juthani-Mehta M, Allore HG. Design and analysis of longitudinal trials of antimicrobial use at the end of life: to give or not to give? Therapeutic Advances In Drug Safety 2019, 10: 2042098618820210. PMID: 30800269, PMCID: PMC6378640, DOI: 10.1177/2042098618820210.Peer-Reviewed Original ResearchTerminal cancer patientsAntimicrobial useEnd of lifePalliative careCancer patientsLongitudinal trialBurden of medicationsCessation of medicationHealth literacy interventionsAntimicrobial therapyAntimicrobial prescribingHealth literacyTrial designComparative trial designTrial dataTrial periodMedicationsPatientsTrialsCareLongitudinal modelingLiteracy interventionsPrescribingTherapyInfection
2016
Methodology to Estimate the Longitudinal Average Attributable Fraction of Guideline-recommended Medications for Death in Older Adults With Multiple Chronic Conditions
Allore HG, Zhan Y, Cohen AB, Tinetti ME, Trentalange M, McAvay G. Methodology to Estimate the Longitudinal Average Attributable Fraction of Guideline-recommended Medications for Death in Older Adults With Multiple Chronic Conditions. The Journals Of Gerontology Series A 2016, 71: 1113-1116. PMID: 26748093, PMCID: PMC4945884, DOI: 10.1093/gerona/glv223.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overCardiovascular DiseasesDrug PrescriptionsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMedicareMultiple Chronic ConditionsPractice Guidelines as TopicRetrospective StudiesSurveys and QuestionnairesSurvival RateThiazidesTreatment OutcomeUnited StatesConceptsMultiple chronic conditionsAverage attributable fractionChronic conditionsAttributable fractionCardiovascular conditionsHeart failureMedicare Current Beneficiary Survey participantsRenin-angiotensin system blockersGuideline-recommended medicationsMore chronic conditionsAge-stratified modelsSystem blockersBeta blockersCardiovascular medicationsOral medicationsAtrial fibrillationMedication effectsMedicationsAge strataParticipant characteristicsOlder adultsSurvivalThiazidesBlockersAge